CIGB 247

Drug Profile

CIGB 247

Alternative Names: Antigen p64K hVEGFKDR adjuvant NAcGM3 VSSP; CIGB 247 V; CIGB-247; CIGB-247-V-vaccine; hVEGFKDR p64K antigen NAcGM3 VSSP adjuvant; hVEGFKDR p64K vaccine; hVEGFKDR- p64K antigen/adjuvant NAcGM3/VSSPs; p64K hVEGFKDR vaccine

Latest Information Update: 23 Feb 2016

Price : $50

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
  • Class Cancer vaccines; Eye disorder therapies
  • Mechanism of Action Immunostimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours
  • Preclinical Age-related macular degeneration

Most Recent Events

  • 22 Feb 2016 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Cuba (SC)
  • 13 Jan 2015 Center for Genetic Engineering and Biotechnology plans a phase I/II trial for Choroidal neovascularisation secondary to age-related macular degeneration in Cuba (RPCEC00000189)
  • 01 Jan 2015 Preclinical trials in Choroidal neovascularisation in Cuba prior to January 2015 (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top